C4 Therapeutics (CCCC) Retained Earnings (2019 - 2026)
C4 Therapeutics' quarterly Retained Earnings came in at -$763.8 million in Q1 2026, down 15.73% year-on-year from -$906.4 million in Q1 2025, and down 3.4% quarter-over-quarter from -$738.7 million in Q4 2025.
C4 Therapeutics has reported Retained Earnings for 8 years, with the latest figure at -$763.8 million in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings fell 15.73% year-over-year to -$763.8 million; the trailing twelve-month figure through Mar 2026 stood at -$763.8 million (down 15.73% YoY), and the FY2025 full-year result was -$738.7 million, down 1393860.38% from the prior year.
- Retained Earnings for Q1 2026 stood at -$763.8 million, down from -$738.7 million in the prior quarter.
- The five-year high for Retained Earnings was $53000.0 in Q4 2024, with the low at -$763.8 million in Q1 2026.
- Average Retained Earnings over 5 years is -$332.7 million, with a median of -$358.7 million recorded in 2022.
- Year-over-year, Retained Earnings jumped 100.01% in 2024 and tumbled 1393860.38% in 2025.
- Tracing CCCC's Retained Earnings over 5 years: stood at -$395.9 million in 2022, then tumbled by 33.47% to -$528.4 million in 2023, then jumped by 100.01% to $53000.0 in 2024, then plunged by 1393860.38% to -$738.7 million in 2025, then fell by 3.4% to -$763.8 million in 2026.
- The last three Retained Earnings figures came in at -$763.8 million (Q1 2026), -$738.7 million (Q4 2025), and -$718.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | C4 Therapeutics | 561.03 Mn | 325.36 Mn | - | -763.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -763.82 Mn |
| Dec 31, 2025 | -738.69 Mn |
| Sep 30, 2025 | -718.20 Mn |
| Jun 30, 2025 | -30,000.00 |
| Mar 31, 2025 | -660.00 Mn |
| Dec 31, 2024 | 53,000.00 |
| Sep 30, 2024 | -599.13 Mn |
| Jun 30, 2024 | -440,000.00 |
| Mar 31, 2024 | -556.74 Mn |
| Dec 31, 2023 | -528.38 Mn |
| Sep 30, 2023 | -904,000.00 |
| Jun 30, 2023 | -1.77 Mn |
| Mar 31, 2023 | -2.47 Mn |
| Dec 31, 2022 | -395.89 Mn |
| Sep 30, 2022 | -358.71 Mn |
| Jun 30, 2022 | -326.75 Mn |
| Mar 31, 2022 | -3.65 Mn |
| Dec 31, 2021 | -775,000.00 |
| Sep 30, 2021 | -252.06 Mn |
| Jun 30, 2021 | -69,000.00 |
| Mar 31, 2021 | -204.79 Mn |
| Dec 31, 2020 | 13,000.00 |
| Sep 30, 2020 | 8,000.00 |
| Dec 31, 2019 | -117.49 Mn |